{"id":"control-tetanus-vaccine-adsorbed","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"5–15","effect":"Fever"},{"rate":"5–10","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108876","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tetanus vaccine, adsorbed contains inactivated tetanus toxoid (a detoxified form of the tetanus toxin produced by Clostridium tetani) adsorbed onto aluminum hydroxide or aluminum phosphate. The adjuvant enhances the immunogenicity of the toxoid, promoting a robust humoral immune response that generates protective antibodies against tetanus toxin, conferring immunity against tetanus infection.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against tetanus toxin by presenting inactivated tetanus toxoid adsorbed onto an aluminum salt adjuvant.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:33.534Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of tetanus in infants, children, and adults"}]},"trialDetails":[{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06056050","phase":"PHASE1","title":"A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":180},{"nctId":"NCT06708286","phase":"PHASE2, PHASE3","title":"A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1820},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT06817187","phase":"PHASE3","title":"Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-16","conditions":"Streptococcus Pneumoniae Infections","enrollment":1110},{"nctId":"NCT06120751","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Tetanus","enrollment":1000},{"nctId":"NCT06123663","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-20","conditions":"Tetanus","enrollment":60},{"nctId":"NCT06049940","phase":"PHASE3","title":"Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-09-01","conditions":"Tetanus","enrollment":1260},{"nctId":"NCT06360250","phase":"EARLY_PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2024-04-10","conditions":"Clostridium Tetanus","enrollment":190},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT05870618","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT05870631","phase":"PHASE4","title":"Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT )","status":"UNKNOWN","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2023-05","conditions":"Vaccine Reaction","enrollment":480},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01187433","phase":"PHASE2","title":"Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":150},{"nctId":"NCT01735084","phase":"PHASE4","title":"Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2013-03-12","conditions":"Otitis Media, Febrile Illness, Cough","enrollment":261},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":"HIV Infection","enrollment":202},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01764256","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-12","conditions":"Rotavirus Infection","enrollment":48},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01174849","phase":"PHASE4","title":"Pneumococcal Vaccines Early and in Combination","status":"COMPLETED","sponsor":"Menzies School of Health Research","startDate":"2011-08","conditions":"Otitis Media","enrollment":425},{"nctId":"NCT01529645","phase":"PHASE1","title":"Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2012-03","conditions":"Pertussis, Whooping Cough, Tetanus","enrollment":420},{"nctId":"NCT00857311","phase":"PHASE1","title":"MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-05","conditions":"Hepatitis C","enrollment":17},{"nctId":"NCT00287092","phase":"PHASE3","title":"Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-02","conditions":"Pertussis, Diphtheria, Tetanus","enrollment":807},{"nctId":"NCT01367158","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":440},{"nctId":"NCT00707148","phase":"PHASE1","title":"Pertussis Vaccine in Healthy Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-01","conditions":"Diphtheria, Pertussis, Tetanus","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Control tetanus vaccine, adsorbed","genericName":"Control tetanus vaccine, adsorbed","companyName":"Sinovac Life Sciences Co., Ltd.","companyId":"sinovac-life-sciences-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against tetanus toxin by presenting inactivated tetanus toxoid adsorbed onto an aluminum salt adjuvant. Used for Prevention of tetanus in infants, children, and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}